Wednesday, February 17, 2010

FDA unveils risk-management plan for Amgen / J&J anti-anemia drugs

Physicians who want to prescribe Amgen Inc.'s anti-anemia drugs for cancer patients will have to register and undergo special training under a risk-management plan unveiled Tuesday by the Food and Drug Administration. Amgen also will require physicians to collect signed statements from patients attesting that they have been informed about the dangers of the drugs.

Posted via web from Jack's posterous

No comments: